

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/693,481	10/24/2003	Elazar Rabbani	ENZ-60(CIP)

28171
ENZO BIOCHEM, INC.
527 MADISON AVENUE (9TH FLOOR)
NEW YORK, NY 10022

CONFIRMATION NO. 2531

FORMALITIES LETTER



OC000000016100998

11/23/2005 GWORDDF1 00000025 051135 10693481

02 FC:2201 3500.00 DA
03 FC:2202 21550.00 DA
04 FC:2203 180.00 DA

Date Mailed: 05/24/2005

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

To Download Patent Software, visit <http://www.uspto.gov/web/patents/software.htm>
For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Additional claim fees of \$25230 as a small entity, including any required multiple dependent claim fee, are

required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:


Total additional fee(s) required for this application is **\$25230** for a Small Entity

- Total additional claim fee(s) for this application is **\$25230**
 - **\$3500** for **35** independent claims over 3.
 - **\$21550** for **862** total claims over 20.
 - **\$180** for multiple dependent claim surcharge.

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

.....

*A copy of this notice **MUST** be returned with the reply.*



Office of Initial Patent Examination (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al.

Serial No.: 10/693,481

Filed: October 24, 2003

Title: NOVEL COMPOSITIONS AND METHODS FOR
CONTROLLING THE EXTENDABILITY OF VARIOUS
COMPONENTS USED IN COPYING OR
AMPLIFICATION STEPS

Group Art Unit: 1645

Examiner: Not Yet Known

527 Madison Avenue, 9th Floor
New York, New York 10022
November 18, 2005

FILED BY EXPRESS MAIL

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

ATTN: Mail Stop Missing Parts

**REPLY TO MAY 24, 2005 NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES – FILING DATE GRANTED**

Dear Sirs:

This Reply is directed to the Notice To Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures – Filing Date Granted (the "Notice") that was mailed on May 24, 2005 in connection with this U.S. Patent Application, Serial No. 10/693,481 (the "481 application").

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No.: **EV655205518US**

Deposit Date **November 18, 2005**

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.

Natalie Bogdanos
Natalie Bogdanos
Reg. No. 51,480

11/18/05
Date

Enz-60(CIP)

Elazar Rabbani et al.

Serial No. 10/693,481

Filed: October 24, 2003

Page 2 (Reply to May 24, 2005 Notice To Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures – Filing Date Granted) – November 18, 2005)

In response to the Notice, Applicants, through their attorney, submit the following documents and items:

1. a copy of the Notice, attached herein as Exhibit 1;
2. a Request For An Extension Of Time (Four Months) Under 37 C.F.R. §1.136(a), attached herein as Exhibit 2; and
3. an Amendment, attached herein as Exhibit 3, and its attachment identified as Exhibit A, consisting of a copy of the Sequence Listing as filed on June 28, 2002 in another of Applicants' applications, namely, U.S. Patent Application Serial No. 09/896,897, along with a copy of the self-addressed stamped return postcard acknowledging receipt by the United States Patent and Trademark Office, and Exhibit B, consisting of a statement asserting that the paper and CRF copy of the Sequence Listing are identical, and a computer readable copy.

In connection with this Reply and the concurrently submitted Amendment herewith, Applicants, through their attorney, request that the Sequence Listing, including the compliant computer readable form thereof, submitted to the United States Patent Office on June 28, 2002 in connection with Applicants' related U.S. Patent Application, Serial No. 09/896,897 (the "'897 application"), be made of record in this '481 application. In accordance with 37 CFR §1.821(e), Applicants state that the Sequence Listing, including the compliant computer readable form thereof already on file in connection with Applicants' '897 application, is identical to the Sequence Listing contained in this '481 application. This '481 application is a divisional of the '897 application.

ENZ-60(CIP)

Elazar Rabbani et al.

Serial No. 10/693,481

Filed: October 24, 2003

Page 3 (Reply to May 24, 2005 Notice To Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures – Filing Date Granted) – November 18, 2005)

A response to the May 24, 2005 Notice To Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Filing Date Granted, was originally due on July 24, 2005. In accordance with Applicants' request for a four-month extension of time, a response is now due on November 24, 2005. As such, this Reply is being timely filed.

A fee of \$25,230.00 is believed due in connection with this Reply in addition to the fee of \$795.00 that is due in connection with the aforementioned Request For An Extension of Time (Four Months) Under 37 C.F.R. §1.136(a). The United States Patent and Trademark Office is hereby authorized to charge the amount of \$26,025.00 to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Reply, the undersigned may be contacted by telephone at (212) 583-0100 during business hours.

Respectfully submitted,



Natalie Bogdanos
Registration No. 51,480
Attorney for Applicants

ENZO LIFE SCIENCES, INC.
f/k/a Enzo Diagnostics, Inc.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
Telephone: (212) 583-0100; Fax: (212) 583-0150

al/USProsecution/Enz-60(CIP).ReplyToMissingPts.111805

ENZ-60(CIP)

Please date stamp and return to addressee.

APPLICANT: Elazar Rabbani et al.	
TITLE: NOVEL COMPOSITIONS AND PROCESSES FOR ANALYTE DETECTION, QUANTIFICATION AND AMPLIFICATION	
ENCLOSED ARE: <input type="checkbox"/> Application <input type="checkbox"/> Response to OA <input type="checkbox"/> Declaration <input checked="" type="checkbox"/> Amendment Re Sequence Listing <input type="checkbox"/> Drawings <input type="checkbox"/> Issue Fee <input type="checkbox"/> Assignment <input checked="" type="checkbox"/> Other (see below)	
<input checked="" type="checkbox"/> PAPER SEQUENCE LISTING AND SEQUENCE LISTING in computer readable form	<input checked="" type="checkbox"/> Express Mail Label No. EL 831284074US mailed 6/28/02
<input checked="" type="checkbox"/> Declaration re sequence listing	<input type="checkbox"/> First Class Mailing Date
<input type="checkbox"/>	Serial No. 09/896,897 filed 6/30/01
	Docket No. ENZ-6C

Please date stamp and return to addressee.

APPLICANT: Elazar Rabbani et al.	
TITLE: NOVEL COMPOSITIONS AND PROCESSES FOR ANALYTE DETECTION, QUANTIFICATION AND AMPLIFICATION	
ENCLOSED ARE: <input type="checkbox"/> Application <input type="checkbox"/> Response to OA <input type="checkbox"/> Declaration <input checked="" type="checkbox"/> Amendment Re Sequence Listing <input type="checkbox"/> Drawings <input type="checkbox"/> Issue Fee <input type="checkbox"/> Assignment <input checked="" type="checkbox"/> Other (see below)	
<input checked="" type="checkbox"/> PAPER SEQUENCE LISTING AND SEQUENCE LISTING in computer readable form	<input checked="" type="checkbox"/> Express Mail Label No. EL 831284074US mailed 6/28/02
<input checked="" type="checkbox"/> Declaration re sequence listing	<input type="checkbox"/> First Class Mailing Date
<input type="checkbox"/>	Serial No. 09/896,897 filed 6/30/01
	Docket No. ENZ-60

